<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TENECTEPLASE RECOMBINANT</span><br/>(ten-ect'e-plase)<br/><span class="topboxtradename">TNKase<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">thrombolytic enzyme</span><br/><b>Prototype: </b>Alteplase<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Tenecteplase (TNK-tPA) is a third generation thrombolytic agent with advantages over alteplase: Longer half-life, more rapid
         thrombolysis, greater fibrin specificity. Also, rate of noncerebral bleeding is less than in alteplase.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective in producing thrombolysis of a clot involved in a myocardial infarction.</p>
<h1><a name="uses">Uses</a></h1>
<p>Reduction of mortality associated with acute myocardial infarction (AMI).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Active internal bleeding; history of CVA; intracranial or intraspinal surgery with 2 mo; intracranial neoplasm; arteriovenous
         malformation, or aneurysm; known bleeding diathesis; severe uncontrolled hypertension.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Recent major surgery, previous puncture of compressible vessels, CVA, recent GI or GU bleeding, recent trauma; hypertension,
         mitral valve stenosis, acute pericarditis, bacterial endocarditis; severe liver or kidney disease; hemorrhagic ophthalmic
         conditions; septic thrombophlebitis or occluded, infected AV cannula; advanced age; concurrent administration of oral anticoagulants,
         recent administration of GP IIb/IIIa inhibitors, condition involving bleeding. Pregnancy (category C), lactation. Safety and
         efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Myocardial Infarction</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> Infuse dose over 5 sec, 60 kg, 30 mg; <i>6070 kg,</i> 35 mg; <i>7080 kg,</i> 40 mg; <i>8090 kg,</i> 45 mg; &gt;<i>90 kg,</i> 50 mg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Read and follow instructions supplied with TwinPak<sup><small>TM</small></sup> Dual Cannula Device. Withdraw 10 mL of sterile
                  water for injection from the supplied vial; inject entire contents into the TNKase vial directing the diluent stream into
                  the powder. Gently swirl until dissolved but do not shake. The resulting solution contains 5 mg/mL. Withdraw the appropriate
                  dose and discard any unused solution. Follow directions supplied with TwinPak<sup><small>TM</small></sup> for proper handling
                  of syringe.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Dextrose-containing IV line must be flushed before and after bolus with NS. Give as a single bolus dose over 5 sec. The total
                  dose given should not exceed 50 mg.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store unopened TwinPak<sup><small>TM</small></sup> at <img src="../images/special/lesserorequal.gif"/>30° C (86°
            F) or under refrigeration at 2°8° C (36°46° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span>
<span class="speceff-life">Major bleeding</span>, <span class="speceff-common">hematoma,</span> GI bleed, bleeding at puncture site, hematuria, pharyngeal, epistaxis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Unreliable results for <span class="alt">coagulation test I</span> and measures of <span class="alt">fibrinolytic activity.</span>
</p>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Half-Life:</span> 90130 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Avoid IM injections and unnecessary handling or invasive procedures for the first few hours after treatment.</li>
<li>Monitor for S&amp;S of bleeding. Should bleeding occur, discontinue concomitant heparin and antiplatelet therapy; notify physician.</li>
<li>Monitor cardiovascular and neurologic status closely. Persons at increased risk for life-threatening cardiac events include
            those with: A high potential for bleeding, recent surgery, severe hypertension, mitral stenosis and atrial fibrillation, anticoagulant
            therapy, and advanced age.
         </li>
<li>Lab tests: Baseline and 1 h after administration of drug determine cardiac enzymes, circulating myoglobin, cardiac troponin-1,
            creatine kinase-MB; Hgb &amp; Hct post-infusion.
         </li>
<li>Coagulation parameters may not predict bleeding episodes.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of the following immediately: A sudden, severe headache; any sign of bleeding; signs or symptoms of hypersensitivity
            (see Appendix F).
         </li>
<li>Stay as still as possible and do not attempt to get out of bed until directed to do so.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>